Recruiting
Phase 3

VK2735 Oral

Sponsor:

Viking Therapeutics, Inc.

Code:

NCT07868939

Conditions

Weight Loss

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

VK2735 Oral

Placebo Comparator

Study Details

Brief summary:

This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.

Conditions

Weight Loss

Study ID

NCT07868939

Start date

Nov, 2026

Status verified date

Nov, 2026

Completion date

Dec, 2028

Anticipated

Primary completion date

Oct, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Age ≥18 years of age at the time of signing the informed consent.
2. Body mass index (BMI) ≥ 27 kg/m2
3. Have Type 2 Diabetes Mellitus according to the American Diabetes Association (See Section 12.5), with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Participants with HbA1c between 6.5%-6.9% or 11.0%-11.5% are allowed to have a single HbA1c retesting to confirm eligibility. Type 2 Diabetes Mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.

Exclusion Criteria:

1. History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation
2. Self-reported body weight change of 5% or more within 3 months of screening
3. Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery (except for liposuction or abdominoplasty if performed >1 year prior to screening)
4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
5. Have Type 1 Diabetes Mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 Diabetes Mellitus (T2DM)
6. Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening

• Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG < 54 mg/dL.
7. Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values > 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization
8. Have non-proliferative diabetic retinopathy that requires acute treatment OR diabetic macular edema OR proliferative diabetic retinopathy identified during a dilated fundoscopy examination performed within 3 months of screening. Please see Section 7.6.
9. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
10. History of acute or chronic pancreatitis
11. Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial/total thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening.

Study Design

Enrollment

560 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

placebo comparator: Placebo Assignment

Placebo comparator orally once daily

experimental: Active Assignment (Dose 1)

VK2735 Dose level 1 orally once daily

experimental: Active Assignment (Dose 2)

VK2735 Dose level 2 orally once daily

experimental: Active Assignment (Dose 3)

VK2735 Dose level 3 orally once daily

Interventions

VK2735 Oral

VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily

Placebo Comparator

Placebo comparator administered orally once daily

Primary outcome measure

  • Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily [ Time Frame: 68 weeks ]

Central Contacts and Locations

Locations

Viking Clinical Site #2020

Recruiting

Tucson, Arizona, United States, 85741

Contacts

Viking Clinical Site #2015

Recruiting

Lake Forest, California, United States, 92630

Contacts

Viking Clinical Site #2059

Recruiting

Ocoee, Florida, United States, 34761

Contacts

Viking Clinical Site #2013

Recruiting

Atlanta, Georgia, United States, 30329

Contacts

Viking Clinical Site #2001

Recruiting

Evansville, Indiana, United States, 47714

Contacts

Viking Clinical Site #2046

Recruiting

Indianapolis, Indiana, United States, 46202

Contacts

Viking Clinical Site #2009

Recruiting

Valparaiso, Indiana, United States, 46383

Contacts

Viking Clinical Site #2004

Recruiting

Richfield, Minnesota, United States, 55423

Contacts

Viking Clinical Site #2029

Recruiting

Jackson, Mississippi, United States, 39206

Contacts

Viking Clinical Site #2028

Recruiting

Springfield, Missouri, United States, 65807

Contacts

Viking Clinical Site #2052

Recruiting

Albuquerque, New Mexico, United States, 87107

Contacts

Viking Clinical Site #2039

Recruiting

Binghamton, New York, United States, 13905

Contacts

Viking Clinical Site #2023

Recruiting

Medford, Oregon, United States, 97504

Contacts

Viking Clinical Site #2002

Recruiting

East Greenwich, Rhode Island, United States, 02818

Contacts

Viking Clinical Site #2044

Recruiting

Charleston, South Carolina, United States, 29407

Contacts

Viking Clinical Site #2030

Recruiting

Hendersonville, Tennessee, United States, 37075

Contacts

Viking Clinical Site #2031

Recruiting

Abilene, Texas, United States, 79606

Contacts

Viking Clinical Site #2011

Recruiting

Seattle, Washington, United States, 98105

Contacts

Viking Clinical Site #2042

Recruiting

Spokane, Washington, United States, 99218

Contacts

More Information

Sponsor

Viking Therapeutics, Inc.

Last update posted

Nov 16, 2026

Last verified

Nov, 2026

Keywords

  • body weight changes
  • body weight
  • weight loss

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by Viking Therapeutics, Inc. on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.